INOVIQ Ltd (IIQ.AX)

0.5350 +0.0050 (+0.94%) At close: 02:46PM AEST

INOVIQ Ltd

23 Normanby Road
Notting Hill, VIC 3168
Australia
61 3 9548 7586
https://www.inoviq.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Leearne Maree Hinch B.Sc., B.V.M.S., BSc., M.B.A., M.R.C.V.S.	Chief Executive Officer	496.25k	N/A	N/A
Mr. Mark Edwards BAcc, C.A., CA	CFO & Company Secretary	186.33k	N/A	N/A
Prof. Gregory Edward Rice BSc (Hons), GradDipMgt, MHA, Ph.D.	Chief Scientific Officer	318.82k	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

INOVIQ Ltd engages in the research, development, and commercialization of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET for capturing and isolating exosomes from liquid biopsy sample. Its cancer diagnostic pipeline includes blood tests in development for ovarian, breast, and other cancers. The company was formerly known as BARD1 Life Sciences Limited and changed its name to INOVIQ Ltd in December 2021. INOVIQ Ltd was incorporated in 1983 and is headquartered in Notting Hill, Australia.

Corporate governance

INOVIQ Ltd’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.